MSH|^~\&|Reports|CML||41504|200507141536-500||ORU^R01||1|2.3PID|1|7859||5175099484^RK^ON|PENIINS^IRAAS||19731026|F|||||9690571745ORC|NW|CC63208|||F|||||||248788^DCSYDA DS DL H|||20040713OBR|1|CC63208||111R^GLUCOSE RANDOM||20040713|20040713|||||||||248788^DCSYDA DS DL H|||||||||FOBX|1|ST|3080^GLUCOSE RANDOM|CHEMISTRY^^|5.5|MMOL/L|3.3-7.8||||F||303^1003080||70OBR|2|CC63208||067^CREATININE||20040713|20040713|||||||||248788^DCSYDA DS DL H|||||||||FOBX|1|ST|3180^CREATININE|CHEMISTRY^^|66|UMOL/L|60-115||||F||303^1003180||70OBR|3|CC63208||252^URIC ACID (URATE)||20040713|20040713|||||||||248788^DCSYDA DS DL H|||||||||FOBX|1|ST|3200^URATE|CHEMISTRY^^|360|UMOL/L|120-400||||F||303^1003200||70OBR|4|CC63208||226^SODIUM||20040713|20040713|||||||||248788^DCSYDA DS DL H|||||||||FOBX|1|ST|3210^SODIUM|CHEMISTRY^^|143|MMOL/L|135-146||||F||303^1003210||70OBR|5|CC63208||204^POTASSIUM||20040713|20040713|||||||||248788^DCSYDA DS DL H|||||||||FOBX|1|ST|3220^POTASSIUM|CHEMISTRY^^|5.1|MMOL/L|3.5-5.2||||F||303^1003220||70OBR|6|CC63208||053^CHLORIDE||20040713|20040713|||||||||248788^DCSYDA DS DL H|||||||||FOBX|1|ST|3230^CHLORIDE|CHEMISTRY^^|106|MMOL/L|95-108||||F||303^1003230||70OBR|7|CC63208||222^SGOT (AST)||20040713|20040713|||||||||248788^DCSYDA DS DL H|||||||||FOBX|1|ST|3370^AST|CHEMISTRY^^|27|U/L|6-42||||F||303^1003370||70OBR|8|CC63208||191^PHOSPHATASE ALKALINE||20040713|20040713|||||||||248788^DCSYDA DS DL H|||||||||FOBX|1|ST|3360^ALK PHOS|CHEMISTRY^^|45|U/L|30-110||||F||303^1003360||70OBR|9|CC63208||030^BILRUBIN TOTAL||20040713|20040713|||||||||248788^DCSYDA DS DL H|||||||||FOBX|1|ST|3340^TOTAL BILIRUBIN|CHEMISTRY^^|10.0|UMOL/L|0.0-23.0||||F||303^1003340||70OBR|10|CC63208||393^COMPLETE BLOOD COUNT||20040713|20040713|||||||||248788^DCSYDA DS DL H|||||||||FOBX|1|ST|2010^HEMOGLOBIN|HEMATOLOGY^^|139|G/L|115-165||||F||201^1002010||70OBX|2|ST|2013^HEMATOCRIT|HEMATOLOGY^^|0.419|L/L|0.37-0.47||||F||201^1002013||70OBX|3|ST|2016^WBC COUNT|HEMATOLOGY^^|7.0|X10 9/L|4.0-11.0||||F||201^1002016||70OBX|4|ST|2019^RBC COUNT|HEMATOLOGY^^|4.94|X10 12/L|3.80-5.80||||F||201^1002019||70OBX|5|ST|2022^MCV|HEMATOLOGY^^|84.8|FL|80-97||||F||201^1002022||70OBX|6|ST|2025^MCH|HEMATOLOGY^^|28.2|PG|27.0-32.0||||F||201^1002025||70OBX|7|ST|2028^MCHC|HEMATOLOGY^^|333|G/L|320-360||||F||201^1002028||70OBX|8|ST|2029^RDW|HEMATOLOGY^^|13.8|%|11.0-14.5||||F||201^1002029||70OBX|9|ST|2030^PLATELET COUNT|HEMATOLOGY^^|238|X10 9/L|150-400||||F||201^1002030||70OBX|10|ST|2191^ABSOLUTE:  NEUTROS|HEMATOLOGY^^|3.9|X10 9/L|2.0-7.5||||F||201^1002191||70OBX|11|ST|2193^     (A)   LYMPH|HEMATOLOGY^^|2.5|X10 9/L|1.1-3.3||||F||201^1002193||70OBX|12|ST|2196^     (A)   MONO|HEMATOLOGY^^|0.4|X10 9/L|0.0-0.8||||F||201^1002196||70OBX|13|ST|2197^     (A)   EOS|HEMATOLOGY^^|0.1|X10 9/L|0.0-0.5||||F||201^1002197||70OBX|14|ST|2198^     (A)   BASO|HEMATOLOGY^^|0.0|X10 9/L|0.0-0.2||||F||201^1002198||70OBX|15|ST|2107^RBC MORPHOLOGY|HEMATOLOGY^^|NORMAL||||||F||203^1002107||70OBX|16|ST|2111^PLATELETS|HEMATOLOGY^^|NORMAL||||||F||203^1002111||70OBR|11|CC63208||445^PROTHROMBIN TIME||20040713|20040713|||||||||248788^DCSYDA DS DL H|||||||||FOBX|1|ST|2165^  I.N.R.|HEMATOLOGY^^COAGULATION|1.1||0.8-1.2||||F||235^1002165||70NTE|1|L|                          NTE|2|L|      RECOMMENDED I.N.R. RANGENTE|3|L|------------------------------------NTE|4|L|THROMBOEMBOLISM RISK       2.0 - 3.0NTE|5|L|PROSTHETIC HEART VALVE     2.5 - 3.5NTE|6|L|                       OBR|12|CC63208||462^PARTIAL THROMBOPLASTIN TIME||20040713|20040713|||||||||248788^DCSYDA DS DL H|||||||||FOBX|1|ST|2169^  ACTIVATED PTT|HEMATOLOGY^^COAGULATION|30|S|24-36||||F||235^1002169||70NTE|1|L|**********************************NTE|2|L|* Please note new reference range*NTE|3|L|**********************************OBR|13|CC63208||679^RUBELLA||20040713|20040713|||||||||248788^DCSYDA DS DL H|||||||||FOBX|1|ST|3765^RUBELLA|RIA^^|59|IU/ML|> 10||||F||435^1003765||70NTE|1|L|IMMUNEOBR|14|CC63208||482^ANTIBODY SCREEN||20040713|20040713|||||||||248788^DCSYDA DS DL H|||||||||FOBX|1|ST|2366^ANTIBODY SCREEN|HEMATOLOGY^^|||||||F||260^1002366||70NTE|1|L|NO CLINICALLY SIGNIFICANTNTE|2|L|ANTIBODIES PRESENTOBR|15|CC63208||490^BLOOD GROUP ABO AND RH (D)||20040713|20040713|||||||||248788^DCSYDA DS DL H|||||||||FOBX|1|ST|2345^BLD GROUP AND RH|HEMATOLOGY^^|O POSITIVE||||||F||255^1002345||70OBR|16|CC63208||9000^VDRL||20040713|20040713|||||||||248788^DCSYDA DS DL H|||||||||FOBX|1|ST|9000^VDRL-SCREEN|REFERRED^^|||||||F||900^1009000||90NTE|1|L|REPORTED DIRECTLY BY PUBLIC HEALTH LABORATORIES.OBR|17|CC63208||347^DHEA SULPHATE||20040713|20040713|||||||||248788^DCSYDA DS DL H|||||||||FOBX|1|ST|4347^DHEA SULPHATE|RIA^^|*    3.3 *|UMOL/L||A|||F||411^1004347||70NTE|1|L|* REVIEW *NTE|2|L|* RESULT *NTE|3|L|DHEA-S REFERENCE RANGE   (UMOL/L)  NTE|4|L|=================================NTE|5|L|AGE (YEARS)    FEMALE      MALENTE|6|L|---------------------------------NTE|7|L|NEWBORN      4.5-10.0    4.5-10.0NTE|8|L|  1-12         < 5.0      < 5.0NTE|9|L| 13-29         <11.0      <11.0NTE|10|L| 30-39         < 7.3      <14.0NTE|11|L| 40-49         < 6.5      <14.1NTE|12|L| 50-59         < 5.4      < 8.4NTE|13|L| 60-69         < 3.5      < 7.9NTE|14|L| 70-79         < 2.4      < 4.7NTE|15|L|  NTE|16|L|  NTE|17|L|  NTE|18|L|  OBR|18|CC63208||333^17-OH PROGESTERONE||20040713|20040713|||||||||248788^DCSYDA DS DL H|||||||||FOBX|1|ST|9235^17-OH PROGESTERONE|RIA^^|*    2.9 *|NMOL/L||A|||F||411^1009235||92NTE|1|L|* REVIEW *NTE|2|L|* RESULT *NTE|3|L|Female:  Follicular          0.8 - 4.2NTE|4|L|         Luteal              1.4 - 12.5NTE|5|L|         Post-Menopausal     0.6 - 5.2NTE|6|L|         Oral Contraceptive  0.5 - 7.6OBR|19|CC63208||305^ANDROSTENEDIONE||20040713|20040713|||||||||248788^DCSYDA DS DL H|||||||||FOBX|1|ST|4349^ANDROSTENEDIONE|RIA^^|10.3|NMOL/L|||||F||411^1004349||70NTE|1|L|REFERENCE RANGE:     NMOL/LNTE|2|L|MALE              2.1 - 10.8NTE|3|L|FEMALE            1.0 - 11.5OBR|20|CC63208||HP17^ANTI-NUCLEAR ANTIBODIES||20040713|20040713|||||||||248788^DCSYDA DS DL H|||||||||FOBX|1|ST|2615^  ANA|HEMATOLOGY^^|NEGATIVE||NEGATIVE||||F||275^1002615||70OBR|21|CC63208||500RA^RHEUMATOID FACTOR||20040713|20040713|||||||||248788^DCSYDA DS DL H|||||||||FOBX|1|ST|2500^RHEUMATOID FACTOR|HEMATOLOGY^^|< 20|KU/L|BELOW 20||||F||270^1002500||70OBR|22|CC63208||340^TESTOSTERONE||20040713|20040713|||||||||248788^DCSYDA DS DL H|||||||||FOBX|1|ST|4125^TESTOSTERONE|RIA^^|3.7|NMOL/L|||||F||410^1004125||70NTE|1|L| NTE|2|L|TESTOSTERONE REF. RANGE  NTE|3|L|--------------------------NTE|4|L|FEMALE:            NMOL/LNTE|5|L| PRE-PUBERTAL      < 1.0NTE|6|L| POST-MENOPAUSAL   0.3-1.2NTE|7|L| NTE|8|L| ADULT             0.3-4.0OBR|23|CC63208||608^FREE TESTOSTERONE||20040713|20040713|||||||||248788^DCSYDA DS DL H|||||||||FOBX|1|ST|4135^FREE TESTOSTERONE|RIA^^|6.6|PMOL/L|< 9.0||||F||410^1004135||70OBR|24|CC63208||9096^HIV||20040713|20040713|||||||||248788^DCSYDA DS DL H|||||||||FOBX|1|ST|9096^HIV|REFERRED^^|||||||F||900^1009096||70NTE|1|L|REPORTED DIRECTLY BY PUBLIC HEALTH LABORATORIES.OBR|25|CC63208||9020^CYTOMEGALOVIRUS||20040713|20040713|||||||||248788^DCSYDA DS DL H|||||||||FOBX|1|ST|9020^CYTOMEGALOVIRUS|REFERRED^^|||||||F||900^1009020||90NTE|1|L|REPORTED DIRECTLY BY PUBLIC HEALTH LABORATORIES.OBR|26|CC63208||580^HEP A AB(IgG+IgM)||20040713|20040713|||||||||248788^DCSYDA DS DL H|||||||||FOBX|1|ST|4230^HEP A AB(IgG+IgM)|RIA^^HEPATITIS INVESTIGATION:|NEGATIVE||NEGATIVE|A|||F||404^1004230||70OBR|27|CC63208||4607^HEP B SURFACE ANTIGEN||20040713|20040713|||||||||248788^DCSYDA DS DL H|||||||||FOBX|1|ST|4200^HEP Bs ANTIGEN|RIA^^|NEGATIVE||NEGATIVE|A|||F||405^1004200||70OBR|28|CC63208||4609^HEP B CORE ANTIBODY||20040713|20040713|||||||||248788^DCSYDA DS DL H|||||||||FOBX|1|ST|4210^HEP B core AB|RIA^^|NEGATIVE||NEGATIVE|A|||F||405^1004210||70OBR|29|CC63208||4037^HEPATITIS C ANTIBODY||20040713|20040713|||||||||248788^DCSYDA DS DL H|||||||||FOBX|1|ST|4237^HEPATITIS C AB|RIA^^|NEGATIVE||NEGATIVE|A|||F||407^1004237||70OBR|30|CC63208||700^DOCUMENTATION FEE||20040713|20040713|||||||||248788^DCSYDA DS DL H|||||||||FFTS|1